Immuno-oncology
From the Journals
Feds aim to streamline gene therapy oversight
“It seems reasonable to envision a day when gene therapy will be a mainstay of treatment for many diseases,” Dr. Collins and Dr. Gottlieb wrote....
From the Journals
EGFR-mutant NSCLC may still respond to PD-1 blockade
A woman presenting with EGFR-mutant non–small-cell lung cancer has shown high PD-L1 expression and responded well to PD-1 inhibitors.
Conference Coverage
Phase 2 trial: Dendritic cell vaccine maintenance prolongs PFS in EOC
DCVAC maintenance after chemotherapy prolonged progression-free survival by almost 6 months in EOC patients who have undergone primary debulking...
From the Journals
Third-line avelumab for gastric cancer safer than chemotherapy
Although no primary or secondary endpoints were met, avelumab demonstrated similar antitumor activity, compared with chemotherapy.
Conference Coverage
No survival boost with atezolizumab vs. regorafenib in mCRC
BARCELONA – There was no overall or progression-free survival benefit from the PD-L1 inhibitor with or without cobimetinib vs. regorafenib alone...
News
FDA grants accelerated approval to ipilimumab/nivolumab combo for CRC
The combo is approved for microsatellite instability-high or mismatch repair deficient metastatic CRC that has progressed.
From the Journals
Immunotherapies extend survival for melanoma patients with brain metastases
Patients with melanoma brain metastases receiving first-line checkpoint blockade immunotherapy had a 91% increase in 4-year survival.
Conference Coverage
Checkpoint inhibitors in autoimmune disease: More flares, better cancer outcomes
AMSTERDAM –
From the Journals
PFS does not capture the benefit of PD-1 inhibitors
The protective effects of treatment were higher for OS than for PFS.
Conference Coverage
KEYNOTE-427: Pembrolizumab monotherapy shows promise in accRCC
CHICAGO – Pembrolizumab monotherapy shows promising efficacy and tolerability in treatment-naive patients with accRCC in the phase 2 KEYNOTE-427...
Conference Coverage
Hints of nivolumab efficacy seen in biliary tract cancers
BARCELONA – Five patients with intrahepatic cholangiocarcinomas or gallbladder tumors had partial but durable responses in a phase 2 trial.